The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
From Mr. Market of course. But at what price?
but where are they going to get any shares?
Always put your money with the big money! I think our share now is attracting some hefty buys a great sign of confidence! I think the big players now sense this is gonna give some BIG Returns!
stay calm yuyus - plenty more where those came from - and soon....
AND ANOTHER AT £81.93 K
late trade reported 14th may a big one £284k
think that this weeks events are a massive boon for AGL ,and a lot of international press also
Some great papers and reviews and some amazing soundbites
Forgot to mention Fidelity also holds 5.25%... I think Softbank would be interested in this health tech play too..
300m Market Cap is pretty modest considering the potential of this tech to disrupt the market... further upside IMO. Morgan Stanley with 6.5% entered at a good time! I guess other IIs may be interested getting in while it is a bargain. IMO DYOR.
i think thats the point bojo , lots of these shares are in sticky hands with people who wont sell for a long time.
this could cause a big squeeze on the price in the coming weeks
Sells are being bought immediately so the MM get their way and the orders get filled. Not sure why anyone would sell when multiples are just 6 months or so away...
Yes £1.30. Last week it was at £1.08. Glad I added :-)
very pleased to see this - the second of the two I previously mentioned were coming (heard through university networks) but I had no idea it was going to be this important. It will send a shudder through the world of liquid biopsy.
Thank you tomphys.
https://uk.advfn.com/stock-market/london/angle-AGL/share-chat
There you go gio, there is also a telegram group
Could someone post the link to the ADVFN board. I lost it when my computer packed up.
Thanks
SK and Semper Vigilans have been rock solid posters on the ADVFN board for several years.
On the issue of a take-over, Andrew Newland has made it very clear that he is NOT minded to entertain any bids on AGL. He has set a target of a market-cap of c. £5B. This is not irrational. Consider that Illumina, the US giant, announced an $8B deal (then worth £6.2B) to buy out Grail in September, 2020. Grail had no income and were years away from FDA clearance for their liquid biopsy which uses machine-learning algorithms to detect a variety of cancers. At the time, Illumina's CEO, Francis deSouza, stated:
"Early cancer detection is likely to be the largest genomic application over the next 15 years, by far."
This gives some yard-stick for the eventual value of technologies such as Parsortix. This will be an impressive journey for AGL, I think. GLA.
Again this due diligence is from Sicilian Kan on A D V f N site , outstanding poster as always , please all read
Best me to it bravo
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246139
Can somebody from here who is a member of that board thank SK on behalf of those of us on here who are not members or able to logon there. As others have said, Sicilian_kan is an excellent poster. Call me a plagiarist but here it is:
There is a new peer-reviewed article just out. It shows that Parsortix can be used to capture disseminated tumour cells (DTCs) and not just CTCs, achieving over 1,000 fold enrichment of DTCs. DTCs present in the bone marrow are believed to be the originators of metastatic spread, and thus a major cause of mortality in breast cancer patients (which note is the FDA application). The concluding paragraph of the report is "We report that the Parsortix system, an automated size and flow-based CTC enrichment platform can be successfully used to enrich DTCs from BM of BC patients with minor modifications. We demonstrate recovery, enrichment, and downstream molecular analysis similar to that achieved with blood. The Parsortix system has several advantages over current methodologies including the relative ease of operation, minimal handling of specimen and recovery of viable cells." The report and its abstract are below: Disseminated tumors cells (DTCs) present in the bone marrow (BM) are believed to be the progenitors of distant metastatic spread, a major cause of mortality in breast cancer patients. To better understand the behavior and therapeutic vulnerabilities of these rare cell populations, unbiased methods for selective cell enrichment are required. In this study, we have evaluated a microfluidic-based filtration system (ParsortixR, Angle PLC), previously demonstrated for use in circulating tumor cell (CTC) capture, to capture BM DTCs. Performance using BM samples was also compared directly to enrichment of CTCs in the peripheral blood (PB) from both metastatic and non-metastatic breast cancer patients. Although the non-specific capture of BM immune cells was significant, the device could routinely achieve significant cytoreduction of BM and PB WBCs and at least 1,000-fold enrichment of DTCs, based on labeled tumor cell spike-in experiments. Detection of previously characterized DTC-associated gene expression biomarkers was greatly enhanced by the enrichment method, as demonstrated by droplet digital PCR assay. Cells eluted from the device were viable and suitable for single cell RNA sequencing experiments. DTCs in enriched BM samples comprised up to 5% of the total cell population, allowing for effective single cell and population-based transcriptional profiling of these rare cells. Use of the Parsortix instrument will be an effective approach to enrich for rare BM DTCs in order to better understand their diverse molecular phenotypes and develop approaches to eradicate these cells to prevent distant disease development in breast cancer patients. hTTps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0246139 I would expect an RNS on this one in the next couple of weeks.
Sicilian Kan is an outstanding poster !
Just seems that there is more news , supportive papers and people and more data forthcoming.
And more of cuff interviews and such like .
Lots more are noticing AGL and taking notice , bearing in mind that circa 35% is held by hopefully long term vice like grip talons .
Fingers crossed for news this week both from AACR 2021 and direct news via RNS from Angle themselves
Fantastic new peer-reviewed article found by Sicilian_kan on ADVFN